Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-NY001
- Development stage
- Unknown
- Lead developer
- WuXi AppTec
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-NY001 is a radiopharmaceutical imaging agent consisting of the humanized monoclonal antibody NY001, which targets Glypican-3 (GPC3), labeled with the positron-emitting radioisotope Zirconium-89 (89Zr). Developed by Noile-Immune Biotech, it is designed for positron emission tomography (PET) imaging to detect and monitor GPC3-expressing tumors, particularly hepatocellular carcinoma (HCC). GPC3 is a cell-surface oncofetal proteoglycan overexpressed in HCC but absent in normal adult liver tissue, making it an ideal target for both therapy and diagnostic imaging. By binding specifically to GPC3, 89Zr-NY001 allows for the non-invasive visualization of tumor burden and the assessment of target expression, which can help in patient selection for GPC3-targeted therapies such as CAR-T cells or antibody-drug conjugates.
- Other names
- Zirconium (89Zr) NY00189Zr-labeled anti-GPC3 antibody
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on 89Zr-NY001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-NY001.